Bauer DC, et al. - In clinical trials of anti-resorptive drugs, physicians examined the treatment-related changes in bone turnover markers (BTMs) and fracture risk reduction. Short-term antiresorptive (AR) treatment-related changes in bone-specific alkaline phosphatase and pro-collagen I N-propeptide were found to strongly predict vertebral fracture treatment efficacy, but not nonvertebral or hip fracture treatment efficacy. In order to predict the anti-vertebral fracture efficacy of new AR compounds or novel dosing regiments with approved AR drugs, change in bone formation markers could be useful.